• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar

information for practice

news, new scholarship & more from around the world


advanced search
  • gary.holden@nyu.edu
  • @ Info4Practice
  • Archive
  • About
  • Help
  • Browse Key Journals
  • RSS Feeds

Hepatitis A, hepatitis B and HPV vaccine needs and coverage in MSM initiating HIV PrEP in a sexual health clinic in Paris

Introduction

Pre-exposure prophylaxis (PrEP) with tenofovir disoproxil/emtricitabine is a powerful tool to prevent HIV acquisition and provides an opportunity to offer comprehensive prevention services, including assessment for sexually transmitted infections and evaluation of immune status towards vaccine-preventable viral infections such those due hepatitis A virus (HAV), hepatitis B virus (HBV) and human papillomavirus (HPV). In addition to the programme in girls aged 11–19, French guidelines recommended HPV vaccination for men who have sex with men (MSM) ≤26 years old in February 20161 and for all boys aged 11–19 in December 2019.2 There are no restrictions on HPV vaccine use beyond these age limits, but the cost is not covered by the French Health Service. In real-life settings, suboptimal vaccination coverage against HPV as well as HBV has been reported among European MSM.3 4

Our objective was to evaluate HAV, HBV and HPV vaccine…

Read the full article ›

Posted in: Journal Article Abstracts on 06/11/2023 | Link to this post on IFP |
Share

Primary Sidebar

Categories

Category RSS Feeds

  • Calls & Consultations
  • Clinical Trials
  • Funding
  • Grey Literature
  • Guidelines Plus
  • History
  • Infographics
  • Journal Article Abstracts
  • Meta-analyses - Systematic Reviews
  • Monographs & Edited Collections
  • News
  • Open Access Journal Articles
  • Podcasts
  • Video

© 1993-2025 Dr. Gary Holden. All rights reserved.

gary.holden@nyu.edu
@Info4Practice